Introduction: Hyperthyroidism is a relatively common disorder caused by different etiologies. Graves’ disease, and toxic-nodular goiter (Plummer’s disease) are among the most common causes. Treatment with radioiodine is considered to be the treatment of choice in many of the patients. Higher biological half-life of ¹³¹I in hyperthyroid patients as compared with patients with differentiate...

CONTEXT Radioiodine is an effective and safe treatment for hyperthyroidism but has been implicated as a risk factor for deterioration or new presentation of Graves' ophthalmopathy (GO). Prophylactic glucocorticoids appear to prevent this effect. OBJECTIVE The objective of this study was to document the course of GO after radioiodine therapy. DESIGN This was a prospective observational study...

We investigated the effect of a single dose of 131I upon thyrotropin receptor antibodies (TRAb) in 21 patients with Graves' disease. The thyrotropin receptor antibodies were assessed by parallel measurements of thyrotropin binding inhibitor immunoglobulin (TBII), thyroid stimulating antibody (TSAb), and thyroid stimulation blocking antibody (TSBAb) in serum by radioreceptor assay, stimulation o...

PURPOSE The radioiodine ablation therapy is required for patients who underwent a total thyroidectomy. Through a comparative review of a low iodine diet (LID) and a restricted iodine diet (RID), the study aims to suggest guidelines that are suitable for the conditions of Korea. MATERIALS AND METHODS The study was conducted with 101 patients. With 24-hour urine samples from the patients after ...

Molecular imaging based personalized therapy has been a fascinating concept for individualized therapeutic strategy, which is able to attain the highest efficacy and reduce adverse effects in certain patients. Theranostics, which integrates diagnostic testing to detect molecular targets for particular therapeutic modalities, is one of the key technologies that contribute to the success of perso...

OBJECTIVE To determine the effect of adjunctive antithyroid drugs on the risk of treatment failure, hypothyroidism, and adverse events after radioiodine treatment. DESIGN Meta-analysis. DATA SOURCES Electronic databases (Cochrane central register of controlled trials, Medline, Embase) searched to August 2006 and contact with experts. Review methods Three reviewers independently assessed tri...

College of Physician’s guidelines on the use of radioactive iodine in hyperthyroidism. The original guidelines, produced in 1995 by a College Working Party, represented the bodies involved in the administration of radioiodine (131I).1 The need for these guidelines emerged from the outcome of a survey, reported in this Journal, which showed considerable variation within the UK in the doses of ra...

CONTEXT To evaluate treatment success and hypothyroidism following main methods of radioiodine therapy of toxic nodular goiter (TNG); calculated versus fixed dose and high versus low dose of radioiodine. EVIDENCE ACQUISITIONS We searched MEDLINE and SCOPUS databases from inception till July 2013, for clinical trials that compared two different methods of radioiodine administration in TNG. The...

Background: Radioiodine is routinely used or proposed for diagnostic and therapeutic purposes: I, I and I for diagnostics and I and I for therapy. When radioiodine-labelled pharmaceuticals are administered to the body, radioiodide might be released into the circulation and taken up by the thyroid gland, which may then be an organ at risk. The aim of this study was to compare dosimetric properti...

UNLABELLED Salivary gland dysfunction has been described in patients undergoing radioiodine therapy but associated lacrimal gland dysfunction (sicca syndrome) has never been reported. We conducted a prospective cohort study with follow-up for up to 3 y in a tertiary care university center to determine the prevalence of sicca syndrome in patients after high-dose radioiodine treatment. METHODS ...